Post

BiRD Response to European Medicine Agency Statement on Ivermectin for Covid-19

The Evidence-Based Medicine Consultancy Ltd responded on Trial Site News to the 22nd March EMA Statement on Ivermectin for COVID-19.

In summary: It is time for regulatory authorities to recognize that ivermectin’s effectiveness in covid-19 has already been demonstrated and that its general safety profile is extremely well-known. In a pandemic situation, regulators should approve this very safe medicine for routine use, at the clinical discretion of any licensed medical practitioner. Further delay can lead only to further unnecessary loss of life.

Evidence-Based Medicine Consultancy Ltd, Trial Site News, 25th March 2021

Read the BiRD rebuttal to the European Medicines Agency’s pronouncement on ivermectin (6 languages):-

English

Translation

Portugese
French
Italian
German
Spanish

Please Contribute

Let's Get Ivermectin Approved

Safe, cheap, beats Covid

Please support our campaign with a monthly or a single amount to help us keep pressure on authorities to approve the safe drug ivermectin that will help beat covid-19 and save lives around the world.

Bird Group/EBMC Squared is a not-for-profit Community Interest Company (CIC).

All funds received will be invested in our activities to promote public health and wellbeing.

Please contribute

Your monthly or single contribution will help us keep pressure on authorities to approve the safe drug ivermectin that will help beat covid-19 and save lives around the world.